BridgeBio Pharma (BBIO) Current Leases (2020 - 2026)

BridgeBio Pharma has reported Current Leases for 7 years, with the latest figure at $4.4 million in Q1 2026.

• Quarterly Current Leases fell 14.78% year-over-year to $4.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.4 million (down 14.78% YoY) and the FY2025 annual result came in at $6.2 million, up 37.42% from the prior year.
• Current Leases retreated to $4.4 million in Q1 2026 per BBIO's latest filing, from $6.2 million in the prior quarter.
• Over five years, Current Leases peaked at $6.2 million in Q4 2025 and troughed at $3.7 million in Q1 2023.
• A 5-year average of $4.5 million and a median of $4.4 million in 2026 frame the typical range for Current Leases.
• The sharpest annual moves came in 2022 and 2025: Current Leases slipped 25.58% in 2022, then jumped 37.42% in 2025.
• Over 5 years, Current Leases stood at $3.7 million in 2022, then increased by 12.33% to $4.1 million in 2023, then advanced by 9.16% to $4.5 million in 2024, then soared by 37.42% to $6.2 million in 2025, then dropped by 28.31% to $4.4 million in 2026.
• According to Business Quant data, Current Leases over the past three periods registered $4.4 million, $6.2 million, and $5.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.